543332 Stock Overview
Manufactures and sells chlor-alkali and related derivatives in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 6/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Epigral Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,944.45 |
| 52 Week High | ₹2,408.35 |
| 52 Week Low | ₹886.50 |
| Beta | -0.13 |
| 11 Month Change | -5.66% |
| 3 Month Change | 0.098% |
| 1 Year Change | 112.48% |
| 33 Year Change | 184.30% |
| 5 Year Change | n/a |
| Change since IPO | 379.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 543332 | IN Chemicals | IN Market | |
|---|---|---|---|
| 7D | -5.9% | -0.8% | 0.5% |
| 1Y | 112.5% | 10.7% | 27.5% |
Return vs Industry: 543332 exceeded the Indian Chemicals industry which returned 9.6% over the past year.
Return vs Market: 543332 exceeded the Indian Market which returned 25.5% over the past year.
Price Volatility
| 543332 volatility | |
|---|---|
| 543332 Average Weekly Movement | 9.0% |
| Chemicals Industry Average Movement | 5.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 543332's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 543332's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 997 | Kaushal Soparkar | www.epigral.com |
Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes value chain, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash products. It also engages in the trading of agrochemical products.
Epigral Limited Fundamentals Summary
| 543332 fundamental statistics | |
|---|---|
| Market cap | ₹83.98b |
| Earnings (TTM) | ₹2.94b |
| Revenue (TTM) | ₹22.73b |
28.6x
P/E Ratio3.7x
P/S RatioIs 543332 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 543332 income statement (TTM) | |
|---|---|
| Revenue | ₹22.73b |
| Cost of Revenue | ₹13.19b |
| Gross Profit | ₹9.55b |
| Other Expenses | ₹6.61b |
| Earnings | ₹2.94b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 68.04 |
| Gross Margin | 42.00% |
| Net Profit Margin | 12.91% |
| Debt/Equity Ratio | 63.9% |
How did 543332 perform over the long term?
See historical performance and comparison